Registry for patients with myelodysplastic syndromes and therapy-related acute myeloid leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This ongoing observational registry collects longitudinal data on patients diagnosed with myelodysplastic syndromes (MDS) and therapy-related acute myeloid leukemia (t-AML). It gathers comprehensive information including demographics, clinical parameters, and health care interventions from participants over 18 years of age. The registry, initiated in 2003, operates under strict ethical guidelines and ensures patient anonymity while recording vital health data. It aims to enhance understanding of these conditions and improve patient care through detailed data collection.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female
* Age \> 18 years
* Patients with myelodysplastic syndrome and therapy-related acute myeloid leukemia
* Able and willing to provide written informed consent

Exclusion Criteria:

* Age \<18 years
* Patient is unwilling or unable to give consent

Where it's running

• Aspasia Stamatoullas
  Rouen, France Recruiting

Study contacts

• Study coordinator: Fatiha CHERMAT, PhD
• Email: fatiha.chermat-ext@aphp.fr
• Phone: +33(0)1 71 20 70 59

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Electronic mindfulness-based music therapy for patients receiving stem cell transplantation

  This trial tests an eHealth mindfulness-based music therapy to see if it improves quality of life and reduces symptoms for adults undergoing stem cell transplantation.

  Recruiting University of Miami · Miami, Florida · NCT07469592

• Orca-T after reduced-intensity or nonmyeloablative conditioning for adults with AML or MDS

  This trial will test whether Orca-T, a donor-derived stem cell and T-cell therapy, is safe and helps adults with acute myeloid leukemia or myelodysplastic syndrome who are receiving reduced-intensity or nonmyeloablative allogeneic stem cell transplants.

  Recruiting at 6 sites Phase 2 Orca Biosystems, Inc. · Los Angeles, California and 5 other locations · NCT07216443

• Testing BH-30236 for relapsed or refractory acute myelogenous leukemia and higher-risk myelodysplastic syndrome

  This study is testing a new drug called BH-30236 to see if it can help adults with relapsed or hard-to-treat acute myelogenous leukemia or higher-risk myelodysplastic syndrome.

  Recruiting at 13 sites Phase 1 BlossomHill Therapeutics · Duarte, California and 12 other locations · NCT06501196

• Testing Enzomenib for patients with relapsed or refractory acute leukemia

  This study is testing a new drug called Enzomenib to see if it can help adults with relapsed or hard-to-treat acute leukemia feel better.

  Recruiting at 80 sites Phase 1/2 Sumitomo Pharma America, Inc. · Newport Beach, California and 103 other locations · NCT04988555

• Age-stratified conditioning regimens to improve outcomes in haploidentical stem cell transplant for myelodysplastic syndrome

  This study tests two conditioning regimens in adults with MDS undergoing haploidentical stem cell transplant to see how age affects outcomes over one year.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT07677306

• FXS0683 in relapsed or refractory blood cancers

  This first‑in‑human study tests FXS0683 in adults with relapsed or refractory B‑cell lymphoma, AML, MDS, or ALL to see if it is safe, how the drug behaves in the body, and whether it shows any antitumor activity.

  Recruiting Phase 1 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Tianjin, Tianjin Municipality · NCT07616089

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.